Sjögren's disease: who works on it

One card per institution. Filter by target, by country, or show only institutions in EU-13 (Horizon Europe widening) countries.

EU-13 is a filter, not a ranking: it only narrows the list.

24 of 200+ institutions, ordered by recent publications and open trials. This is not a ranking of quality.

Terminated, withdrawn and suspended trials with the reason the sponsor gave in the registry, quoted word for word.

• Withdrawn

  Autologous CD19/BCMA Dual-Target CAR-T for Relapsed/Refractory Autoimmune Diseases

  NCT07361094· Beijing Boren Hospital· Updated 15 Oct 2026

  “No participants.”Registry text, quoted unchanged. Source

• Terminated

  A Study to Evaluate the Effects of ASP5502 in Healthy Adults and Adults With Primary Sjögren's Syndrome

  NCT06544642· Astellas Pharma Global Development, Inc.· Updated 14 Sept 2026

  “Company's strategic decision”Registry text, quoted unchanged. Source

• Suspended

  A Study of BEN301 Injection in theTreatment of Autoimmune Diseases

  NCT07527936· RenJi Hospital· Updated 4 Jun 2026

  “company's decision”Registry text, quoted unchanged. Source

• Withdrawn

  Pregnancy and Medically Assisted Conception in Rare Diseases

  NCT02450396· Assistance Publique - Hôpitaux de Paris· Updated 27 Mar 2026

  “Abandonment of the study project”Registry text, quoted unchanged. Source

• Suspended

  Clinical Study on Targeted CD19CAR-T Therapy for Autoimmune Diseases

  NCT06549296· Nanjing Bioheng Biotech Co., Ltd.· Updated 3 Feb 2026

  “R\&D strategy adjustment”Registry text, quoted unchanged. Source

• Terminated

  Study to Evaluate Corneal Neurosensory Abnormalities in Patients With Sjögren's Dry Eye

  NCT06411132· Dompé Farmaceutici S.p.A· Updated 20 Nov 2025

  “The analyses presented are based on a database lock date of 05 March 2025.The study was prematurely interrupted by Dompé following a review of the database, which determined that an acceptable no. of patients was reached to meet the trial objectives.”Registry text, quoted unchanged. Source

• Terminated

  RHPRG4 FOR THE TREATMENT OF SJÖGREN'S RELATED DRY EYE DISEASE

  NCT06520202· Lubris Bio Pty Ltd· Updated 29 Sept 2025

  “Efficacy signal substantial enough to move to a larger sturdy”Registry text, quoted unchanged. Source

• Terminated

  Differences in Corneal Structure and Function in Patients With Sjogrens vs. Non-Sjogrens Dry Eye

  NCT06364657· Johns Hopkins University· Updated 15 Jan 2025

  “The study was prematurely closed to enrollment due to the principal investigator's departure from the institution (Johns Hopkins University).”Registry text, quoted unchanged. Source

• Withdrawn

  Anti-BTLA Agonist Therapy in Subjects With Primary Sjogren's Syndrome

  NCT05781451· Stanford University· Updated 17 Apr 2024

  “Drug unavailable”Registry text, quoted unchanged. Source

• Suspended

  Sjogren's Lung Study

  NCT04843345· Stanford University· Updated 27 Oct 2022

  “Indefinite paused for staffing issues”Registry text, quoted unchanged. Source

Trials whose registry record says individual participant data (IPD) will be shared.

• A Trial in Healthy Adult Participants and Adults With Autoimmune Diseases to Test How HBM7020 is Tolerated and How it Behaves in the Body

  NCT07649265· Otsuka Pharmaceutical Development & Commercialization, Inc.· Source

• A Study of Nipocalimab in Adults With Primary Sjogren's Syndrome (pSS)

  NCT04968912· Janssen Research & Development, LLC· Source

• Nipocalimab in Moderate to Severe Sjogren's Disease

  NCT06741969· Janssen Research & Development, LLC· Source

• Umbilical Cord Mesenchymal Stem Cell Secretome in Patients With Sjogren's Syndrome

  NCT07910526· Universitas Sebelas Maret Hospital· Source

• Safety of Tofacitinib, an Oral Janus Kinase Inhibitor, in Primary Sjogren Disease

  NCT07281456· National Institute of Dental and Craniofacial Research (NIDCR)· Source

• A Study to Evaluate the Efficacy and Safety of Dazodalibep in Participants With Sjögren's Syndrome (SS) With Moderate-to-severe Systemic Disease Activity

  NCT06104124· Amgen· Source

• A Phase 2a/b Study to Assess the Efficacy, Safety and Tolerability of DDY391 in Participants With Sjögren's Disease

  NCT07737743· Novartis Pharmaceuticals· Source

• Characterization of Diseases With Salivary Gland Involvement

  NCT02327884· National Institute of Dental and Craniofacial Research (NIDCR)· Source

• A Randomized, Double-blind 2-arm, Followed by an Open-label 1-arm, NEPTUNUS Extension Study to Assess the Long-term Safety and Efficacy of Ianalumab in Patients With Sjogrens Syndrome.

  NCT05985915· Novartis Pharmaceuticals· Source

• A Study of BMS-986553 in Participants With Refractory Autoimmune Diseases

  NCT07873931· Bristol-Myers Squibb· Source

Find publications on this disease by a MeSH method term, for example a sequencing or imaging method.

• Single-Cell Analysis 15
• Organoids 3
• Mendelian Randomization Analysis 20
• Gene Expression Profiling 31
• Sequence Analysis, RNA 6
• Exome Sequencing 2
• Proteomics 7
• Metabolomics 9
• Mass Spectrometry 1
• Flow Cytometry 11
• Immunohistochemistry 5
• Positron-Emission Tomography 1
• Magnetic Resonance Imaging 17
• Machine Learning 17
• Deep Learning 4
• Cohort Studies 35
• Genome-Wide Association Study 24

See which targets of this disease your abstract mentions, and go to the people working on them.